Oct. 27 (Bloomberg) -- UCB SA raised its full-year profit and revenue forecasts because of slower generic competition to its epilepsy drug Keppra and growing sales of its key medicines Cimzia, Neupro and Vimpat.
UCB sees revenue this year exceeding its previous forecast of about 3.1 billion euros, the company said today in an e- mailed statement. Core earnings per share will be more than 1.80 euros, compared with its previous goal of up to 1.70 euros.
Combined sales of Cimzia, Vimpat and Neupro in the first nine months rose 54 percent to 445 million euros at actual exchange rates, UCB said.
To contact the editor responsible for this story: Andrew Clapham at firstname.lastname@example.org